REVIEW SUMMARY

Latency reversal and viral clearance to cure HIV-1

David M. Margolis,* J. Victor Garcia, Daria J. Hazuda, Barton F. Haynes

BACKGROUND: A central challenge to emerging efforts to cure HIV infection is the persistence of quiescent but replication-competent proviral genomes in resting CD4+T lymphocytes and, to an unknown extent, in other cell populations. Targeted approaches are sought to reverse latency, induce viral antigen expression within formerly latently infected cells, and use immune clearance mechanisms to eradicate persistent infection. Small-molecule HIV latency-reversing agents (LRAs) capable of modulating pathways that control HIV-1 latency are the first tools to be studied in this effort. However, despite the successful reversal of latency, the only clinical interventions to date producing a significant decrease in the viral reservoir involved bone marrow transplantation. Moreover, whether the HIV-1 RNA expression induced by LRAs leads to durable viral protein presentation on the surface of infected cells sufficient to allow immune-mediated clearance is unknown. Because multiple mechanisms are involved in maintaining the transcriptional silence of HIV-1, a combination of LRAs may be necessary to effectively perturb persistent HIV-1 infection. Defining the cells that harbor persistent HIV-1 is technically challenging, burdening the development of antilatency therapy. Last, immune interventions designed to clear persistently infected cells have yet to be combined with LRAs in a successful, coordinated therapeutic strategy.

HIV latency. Potential obstacles to HIV eradication. (A) True virological and transcriptional latency, with little HIV RNA expression, and no detectable HIV antigen presentation. (B) So-called “active latency” with ongoing production of viral RNA and antigen. (C) Proliferation of latently infected cells, driven by homeostatic forces, or by dysregulation of the host gene program by a viral integrant, without viral production. (D) The possibility that de novo infection occurs despite effective ART. (E) Failure of immune clearance owing to viral epitope escape or host immune exhaustion.

OUTLOOK: Although the challenges of latent HIV-1 infection are daunting, the stability of the latent pool over years of antiviral therapy gives hope that an effective perturbation of the homeostasis that maintains the latent pool may allow substantial depletion, and eventually eradication, of persistent infection. The steady advances in animal models of HIV-1 latency, tools for the assessment of persistent infection, LRAs to disrupt latency, and emerging immunotherapeutics to clear persistently infected cells suggest that the first effective combination studies may be close at hand. Such studies will likely represent progress toward the goal of HIV-1 cure while also revealing new challenges to be overcome.

ADVANCES: Histone deacetylase (HDAC) inhibitors have been the most widely investigated LRAs, inducing cell-associated HIV-1 RNA in four clinical studies. The complex nature of the mechanisms that restrict HIV-1 expression of the population of latent integrated proviruses suggests the hypothesis that combinations of agents could more effectively disrupt latency. Numerous in vitro studies support this hypothesis, but thus far, only one animal model study used several LRAs; although results appeared promising, the effect of this combination was not directly assessed.

A study of latently infected cells obtained from HIV-1+ donors on antiretroviral therapy revealed that instantaneous reversal of latency across all cells harboring integrated proviruses may be challenging and suggests that effective LRA strategies will likely need to be delivered serially over time. This study also illustrates the limitations of assessing the persistence of latent infection via HIV-1 RNA expression because a majority of such RNA transcripts are defective and therefore irrelevant. New approaches, such as novel techniques that can quantitate the frequency of rare cells in a large population that are capable of expressing viral antigen, may surmount this challenge.

Other recent efforts have examined the obstacles to clearance of persistent, latent infection. For example, the latent reservoir harbors viral mutant subpopulations that have previously escaped the extent antiviral immune response. Tissue sanctuaries that may be poorly accessed by the cytotoxic T lymphocyte (CTL) response have been described, as has the potential for some LRAs to interfere with CTL activity. Whether the extent of antigen presentation induced by the current generation of LRAs is sufficient to allow targeting and clearance of infected cells remains unknown.

Author affiliations are available in the full article online.

*Corresponding author. Email: dmmargo@med.unc.edu

Cite this as: D. M. Margolis et al., Science 353, aaf6517 (2016). DOI: 10.1126/science.aaf6517

Read the full article at http://dx.doi.org/10.1126/science.aaf6517
Latency reversal and viral clearance to cure HIV-1

David M. Margolis,1,2 J. Victor Garcia,2 Daria J. Hazuda,3 Barton F. Haynes4

Research toward a cure for human immunodeficiency virus type 1 (HIV-1) infection has joined prevention and treatment efforts in the global public health agenda. A major approach to HIV eradication envisions antiretroviral suppression, paired with targeted therapies to enforce the expression of viral antigen from quiescent HIV-1 genomes, and immunotherapies to clear latent infection. These strategies are targeted to lead to viral eradication—a cure for AIDS. Paired testing of latency reversal and clearance strategies has begun, but additional obstacles to HIV eradication may emerge. Nevertheless, there is reason for optimism that advances in long-acting antiretroviral therapy and HIV prevention strategies will contribute to efforts in HIV cure research and that the implementation of these efforts will synergize to markedly blunt the effect of the HIV pandemic on society.

The human immunodeficiency virus (HIV) has been a major burden on society since the virus emerged over 30 years ago. But in less than 2 decades, a remarkable investment and the resultant scientific progress across the biomedical research enterprise and the pharmaceutical industry produced the spectacular success that is now modern antiretroviral therapy (ART) (1). These advances transformed HIV infection from a fatal disease into a manageable chronic illness. The global implementation of ART and HIV prevention efforts are now showing signs of blunting the HIV pandemic (2).

Despite these successes, the stigma of HIV infection and its long-term societal and resource costs remain a substantial challenge. Suppressive, lifelong antiviral therapy alone cannot be the final solution to the HIV pandemic, and thus, recent efforts have focused on interventions that can yield a drug-free remission of HIV infection or even its cure. Drug-free immune control of chronic HIV infection may exact a toll on the host, and many may prefer the complex goal of HIV eradication. At the individual level, ART provides substantial long-term health benefits, and so compared with other foreseeable goals such as drug-free immune control of chronic HIV infection, perhaps only the challenging goal of HIV eradication may be acceptable to some. A number of diverse and novel approaches aimed at finding a cure for HIV are being explored, and encouraging advances have emerged.

The challenge at hand is considerable and is well illustrated both by a singular success and several failures. In the case of Timothy Brown, the Berlin patient, it seems that a series of complex clinical events after the transplantation of CCR5-deficient cells innately resistant to HIV infection led to the complete clearance of infected cells (3, 4). Although limited studies did not detect latently infected cells in the Boston patients after stem cell transplantation (5), or in the Mississippi child (6) treated with potent antiretroviral therapy in the first hours of life, the absence of a durable and potent anti-HIV immune response may have allowed viral rebound. There is little doubt that a considerable and sustained effort will be needed in both basic and translational research to transform these clinical anecdotes into therapeutic approaches that are safe and effective enough to be deployed broadly against the HIV pandemic.

The beginnings of HIV cure research

The initiation of efforts to develop therapeutic strategies to clear HIV infection has led to advances overcoming the obstacles to viral eradication and has illuminated new challenges. Proviral latency—the persistence of quiescent but replication-competent proviral genomes in resting CD4+ T lymphocytes, and to an unknown extent in other cell populations such as myeloid cells—is a central problem for curative strategies (7). A central approach to this problem envisions targeted approaches to reverse latency so that viral antigen is expressed by a formerly latently infected cell and becomes vulnerable to immune clearance mechanisms. Further, such viral clearance mechanisms may require therapeutic or immunomodulatory enhancement strategies such as reversal of anti-HIV-1 effector cell exhaustion.

Host cell–mediated molecular mechanisms maintain the quiescence of HIV-1 gene expression in infected resting CD4+ T lymphocytes, and these mechanisms are potential therapeutic targets for disrupting latency (Fig. 1). One well-defined mechanism contributing to maintenance of latency is the recruitment of histone deacetylases (HDACs) to the HIV promoter in the long terminal repeat (LTR), mediating the formation of a repressive chromatin environment that inhibits LTR transcription and viral production (8–13). The relevance of this mechanism has been validated in resting CD4+ T cells obtained from ART-treated, aviremic, HIV-infected individuals (10, 11, 14, 15–19). The potent HDAC inhibitor, vorinostat induces HIV chromatin acetylation and promoter expression in cell lines and elicits virus production ex vivo from the resting CD4+ T cells of HIV-infected patients on suppressive ART. This effect is achieved without cellular activation, up-regulation of HIV coreceptors, or de novo HIV infection, all of which could increase the number of infected cells in the host (20, 21). Direct proof-of-concept of latency reversal has also been achieved in clinical studies, in which increases in cell-associated HIV-1 RNA production and/or plasma viremia was observed after in vivo administration of the HDAC inhibitors vorinostat, panobinostat, or romidepsin (22–25)—and in one study, the drug disulfiram (26)—to ART-suppressed patients. However, thus far none of these interventions alone has been found to reduce the frequency of latently infected cells.

Although these data are encouraging, challenges for the effective implementation of so-called “latency-reversing agents” (LRAs) have emerged. Several studies have suggested that LRAs, at least when tested after a single drug exposure in vitro, may disrupt latency in only a subset of the population of latently infected cells (27, 28). On the basis of these in vitro studies, combinatorial LRA strategies are widely assumed to be needed to effectively and comprehensively purge the pool of replication-competent, integrated, persistent HIV. Concepts include combining HDAC inhibitors with histone methylation inhibitors (29), and protein kinase C (PKC) agonists with HDAC inhibitors or bromodomain (BRD) inhibitors (30). Toll-like receptor agonists, whose mechanism of action as an LRA is not yet fully defined (31, 32), have appeared promising in nonhuman primate studies. Human trials to test these concepts are in development.

More problematic for the discovery and development of new LRAs is the challenge that the preclinical models used for their study respond in diverse ways to signals known to reverse latency (33). Further, assays using cells from HIV+, ART-treated patients may not fully recapitulate the complexity of latency in vivo (34) because a single pulse of maximal mitogenic activation in vitro does not disrupt latency in all infected cells. This surprising observation suggested that there might be absolute limitations to the effectiveness of a single exposure to even the most potent LRAs. Although serial stimulation in vitro induces expression of a larger proportion of the latently infected population over time (35), the challenge of
developing single or combinatorial therapies that safely disrupt latency in all infected cells over a clinically tractable period of time may be considerable. An additional complication is the recent appreciation that the majority of species of cell-associated HIV RNA expressed in latently infected cells contains substantial mutations and deletions, largely because of the action of APOBECs (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like), a family of cytidine deaminase proteins that efficiently restrict HIV expression (36). Therefore, although the detection of HIV RNA within these cells reveals past infection, many viral genomes detected by means of RNA expression are replication-incompetent. The predominance of defective HIV DNA genomes (37) and incompetent HIV RNA transcripts (34) pose a challenge for investigators wishing to quantitate the latent reservoir and evaluate strategies to deplete it.

Replication-competent HIV can be measured by using the quantitative viral outgrowth assay (QVOA). Although QVOA can measure the frequency of truly latent proviral infection in cohorts of stably treated patients, as documented by independent studies carried out over more than 2 decades (38, 39), the output represents a minimal estimate of the frequency of persistent, latent HIV infection (34). This leaves investigators in a quandary: Measures of integrated HIV DNA vastly overestimate the frequency of true latent HIV infection, as do (to a lesser extent) measures of cell-associated HIV RNA, whereas the QVOA underestimates the size of the latent reservoir.

We suggest that these problems could be circumvented by the development and implementation of more sensitive tools that could assess latency reversal at the level of viral protein production, or the presentation of viral antigen to the immune system. Cells that are capable of expressing viral proteins are more relevant than cells that simply contain replication-defective HIV DNA genomes or express HIV RNA transcripts. Such cells are likely to be more frequent and more easily assayed than those that produce functional virions. This is perhaps the most relevant metric by which to evaluate latency reversal because the current goal of latency reversal is to create targets for immune-based clearance.

**The calculus of viral persistence: Forces that drive the decay of the latent reservoir**

Because latent, persistent HIV infection was described within the resting CD4+ memory T cell, viral quiescence was initially thought to derive principally from the quiescent cellular state of the host T cell, an environment unfavorable to HIV expression (40–43). Over the next decade, studies of HIV transcriptional regulation did not refute that view but modified it, as several specific cellular mechanisms were described that served to enforce proviral quiescence (44). Some cellular mechanisms that enforce proviral latency have now become the rational targets of latency-reversing agents, seeking to inhibit these silencing mechanisms and allow expression of latent provirus (45, 46).

However, recent findings have reignited the debate around two additional mechanisms that could contribute to the persistence of replication-competent provirus: cellular proliferation and ongoing viral replication. HIV-infected patients on long-term ART have now been found to have identical HIV sequences integrated at the same position in the host genome in multiple cells, suggesting that the infected cells had descended from an identical clone via cellular proliferation (47, 48). However, the replication-competence of these proliferating clones remains in question. One study found that all of 75 integrated genomes that were fully sequenced contained lethal mutations or deletions and were replication-incompetent (49). However, this finding should be replicated and expanded because even a small fraction of proliferating but replication-competent HIV genomes could contribute substantially to viral persistence.

The contribution of other cell populations that sequester HIV in a quiescent state and persist for years despite ongoing ART also requires further examination. Latent infection can be established in vivo in naïve and transitional CD4+ T cells, stem memory T cells, and γ-δ T cells (50–54). But the durability of these potential reservoirs in vivo is not understood. Similarly, whereas it is clear that various myeloid cell populations can be infected during untreated HIV viremia (54), the contribution of the persistence of latent infection in these populations to the HIV reservoir in ART-suppressed patients is unclear (55, 56).

Last, the potential contribution of residual virus replication and spread, despite ongoing ART, to HIV persistence remains controversial. Multiple controlled studies of ART intensification have found that additional inhibitors of entry, reverse transcription, integration, and viral protease function had no effect on low-level viremia, arguing that low-level viremia was generated by chronically infected cells and not by ongoing
Fig. 2. Persistent latent infection of memory CD4 cells decays slowly over time. Residual HIV replication and proliferation of latently infected cells might increase the frequency of latent infection, but these forces must be strongly outweighed by those that naturally deplete latent infection because a slow decay of latent infection is uniformly seen in stably treated patients. The goal of antilatency therapy is to effectively accelerate the clearance of persistent infection across all reservoirs of persistent infection. This data, collected over 10 years ago (35), has recently been precisely reproduced in a contemporary patient cohort using improved ART (36). [Adapted by permission from Macmillan Publishers, Nature Med. 2003.]

rounds of replication (57–63). However, in several studies that added an integrase inhibitor to ART-suppressed patients, transient changes in immune activation were seen, potentially because of ongoing replication (64, 65). HIV sequence evolution might be expected in treated patients in whom replication was ongoing. One study reported this within lymph node tissue in patients treated for 6 months (66), a relatively short period of time after initiating ART, but other studies found no evidence of evolution in plasma or tissues in participants in whom durable suppression of viremia had been established for years (67, 68).

Regardless of the final adjudication of these issues, the overall calculus of persistent infection is clear: Once durable and suppressive ART is implemented, all measures of persistent HIV infection are either stable or decay slowly over time. Therefore, although any new persistent infections founded by cellular proliferation or residual replication on a daily basis have the potential to increase the number of latently infected cells, this contribution is apparently slightly outweighed by the number of cells that reactivate or die and leave the quiescent pool on a daily basis (Fig. 2). If this were not the case, the frequency of latent infection would increase over time.

Although not the only possible approach to eradicate HIV infection, the tools are now at hand to implement latency-reversal strategies that create a window of vulnerability within the pool of latently infected cells. LRAs must be implemented effectively in combination with immunotherapeutic approaches that can clear HIV-infected cells that present viral proteins in the context of latency reversal. Such combination eradication approaches, even if only modestly effective, should result in substantial, measurable, and reproducible depletion of persistent infection, the next major step in the development of HIV eradication strategies.

Current approaches to clearance of persistent HIV infection after latency reversal

The clearance of residual HIV infection in the context of prolonged suppression of viral replication by ART is a major challenge for the immune system and for immunotherapies. The targets for clearance are rare populations of cells, induced to express HIV proteins in quantities that are likely to be limited, for which the duration and kinetics of antigen presentation are unknown. Further, these cell populations may be widely distributed across anatomical compartments, and in many patients, the HIV-specific immune response may have waned in the absence of recent antigen exposure and/or may be dysfunctional or depleted owing to the effects of HIV infection on the immune system. Although CD8 T cells are highly effective in targeting and clearing virus-infected cells, and in HIV infection contribute to control of viremia, Deng et al. highlighted the widespread prevalence of CD8 T cell escape mutations in viral genomes found in the resting CD4 T cell reservoir (69). However, within these subjects, CD8 cells capable of targeting other epitopes that lacked mutations were detectable in all patients after peptide stimulation. This suggests that although HIV can rapidly evade the immune system in the setting of unchecked viremia, HIV-infected individuals on ART possess effector cell populations that may be capable of clearing viral species within the latent reservoir.

It is also important to consider the effects of agents used to reverse latency on the various host immune mechanisms that are required to recognize and clear the infected cells. The window of vulnerability induced by latency-reversing agents must be judged not only by the extent of antigen expression within the latent reservoir of ART-suppressed, HIV-infected individuals, but by the ability of immune mediators to act after LRA exposure. One in vitro study suggested that romidepsin and panobinostat—two HDAC inhibitors, the leading class of LRAs—might inhibit the HIV-specific T cell response and thereby reduce the ability of the immune system to clear infection after the reversal of latency (70). But in this study and two others using autologous cells from aviremic HIV-infected patients on ART, the antiviral activity of effector cells was unaffected by exposure to the HDAC inhibitor vorinostat (71, 72). Data from an ongoing study of pulsatile vorinostat therapy given several times a week revealed no evidence that vorinostat exposure reduced the ability of CD8+ T cells or natural killer cells to recognize and clear latently infected cells induced to express HIV ex vivo (73, 74). Similarly, Søgaard (25) found that three weekly doses of romidepsin failed to measurably blunt the HIV-specific T cell response in vivo. Nevertheless, the possibility that, because of the very nature of their cellular targets, LRAs may affect immune function and therefore clearance of infected cells in which latency has been reversed, is an important issue that must be systematically assessed.

However, although LRAs can be selected for minimal impact on the immune response, in many individuals on stable, suppressive ART, the low frequency of HIV-specific CD8+ T cell responses may be insufficient to clear the latent reservoir (75). As described above, this deficiency may be related to CD8+ T cell escape mutations archived in the latent reservoir that arose before the implementation of ART (69, 76–78) and/or to the dysfunctional, or “exhausted,” state of the HIV-specific T cell seen in chronic infection (79). Thus, strategies to strengthen HIV-specific T cell immune responses may be needed.

A number of therapeutic HIV-1 vaccines that might fill this need have been tested, including whole inactivated virus, recombinant proteins or viruses, DNA vectors, or dendritic cell presentation of autologous antigens (80–84). Some vaccines improved HIV-specific immune responses (85), but none to date has allowed sustained ART interruption. However, in such studies the vaccine-induced immune response is asked to fully restrain all HIV replication in the absence of ART, an as-yet unmet milestone. However, for the goal of eradication in the setting of ongoing ART and antilatency therapies, the bar may be much lower because viral replication and therefore viral escape is blocked in the presence of ART.

Further, a small number of vaccine trials have measured the impact of the vaccine on the size of the latent reservoir and seen either no sustained impact on the reservoir (86) or, at best, a small,
transient decline in the frequency of replication-
competent latent infection (87), below a threshold
predicted to be clinically relevant (38). This is
most likely due to the lack of viral expression
in latently infected cells, making these reser-
voirs insensitive to any immune response (7).

Last, such vaccines have not yet been tested
for specific characteristics that may be critical
to allow effective clearance of persistent HIV
infection: recognition of relevant epitopes in
the context of infection emerging from the latent
state; reduction of low-level viremia that persists
during ART; or decrease in the frequency of
latently infected cells (88, 89). These endpoints
should be considered in future studies as well as
use of those HIV-preventive vaccines that have
induced the greatest level of HIV-specific CD8+
cytotoxic T lymphocyte (CTL) in man (90). Vac-
cines that induce T cell responses against con-
served viral epitopes may contribute to the ability
to clear persistent HIV (91–94). Recent data have
demonstrated that attenuated cytomegalovirus
(CMV)-vectorized SIV genes can induce CD8 CTL,
which might eradicate SIV-infected CD4 T cells,
as 50% of macaques appeared cured of acute in-
fec tion (95, 96). A portion of CMV-induced CD8
T cells recognize SIV-infected CD4 T cells atypically
via major histocompatibility complex class II and
human lymphocyte antigen E, potentially repre-
senting a new approach to the clearance of re-
troviral infection (96, 97). Understanding the
mechanisms of atypical CD8 T cell killing of
retroviral-infected CD4 T cells and validation of
the safety and efficacy of CMV-vectored approaches
in humans is needed.

Antibodies that can specifically direct immune
clearance of HIV-infected cells are a new area of
HIV cure research. Cocktails of broadly neutral-
izing antibodies derived from HIV-infected indi-
viduals can bind to virions and virus-infected
CD4 T cells and may be useful tools for curative
strategies (98, 99). Other non-neutralizing HIV
antibodies have been isolated that selectively
target virus-infected CD4 T cells. Engineering of
these Env-targeting antibodies into bispecific
antibodies or chimeric dual-affinity retargeting
antibodies (DARTS) that can target CD8 effector
cells to HIV-infected CD4 T cells is a promising new
strategy (72, 100, 101). Novel immune-augmenting
strategies, such as adjunctive treatment with
immune checkpoint inhibitors, might reawaken
an extant but exhausted or diminished immune
response and facilitate clearance of viral reser-
voirs (102).

Testing latency reversal and clearance

Although informative studies of latency rever-
sal and clearance strategies can be executed in
ex vivo tissue culture models, a full analysis of
curative strategies must be performed in animal
model studies and human clinical trials. Like all
HIV-infected cells, latently infected cells exist
predominantly in tissues, and some anatomic
compartments may differ in drug penetration
or in the access of components of the cellular
and humoral immune response. Therefore, com-
prehensive studies of latency reversal and clear-
ance strategies require extensive tissue monitoring
and sampling that is both practically and ethically
untenable in human studies. Although it is
fortunate that both humanized mouse models
and nonhuman primate models have recently
been advanced so that infection and ART can
be reliably used, both models could benefit from
further optimization in order to address the most
relevant questions related to HIV cure research.

Novel humanized mice models such as the
bone marrow–liver-thymus (BLT) mouse, the
T cell–only mouse (ToM), and the recently
described Myeloid-only mouse (MoM) serve effec-
tively in this capacity (54, 103). Humanized BLT
mice exhibit systemic human reconstitution,
including in the brain, gut, and vaginal mucosa,
with a complete and functional human immune
system. By virtue of only having human T cells,
ToM allow for the investigation of latency pure-
ly in this important compartment. In both of
these models, HIV establishes a chronic, lifelong
infection from which latently infected cells can
be isolated after suppression of viremia ART
(104, 105). Similarly, the availability of a model
deoil of human T cells but with a full com-
plement of myeloid cells (MoM) allows for the
investigation of the contribution of macrophages
onto HIV latency and persistence in the complete
absence of human T cells. The utility of hu-
manized mice for the in vivo analysis of LRAs
and clearance strategies has been demonstrated
(99, 103, 106). BLT and ToM mice allow (i)
the evaluation of different types of highly relevant
viruses for infection, (ii) the analysis of latency
and persistence by virtually all human cell types
that are targets of HIV infection in both the
periphery and tissues, (iii) the evaluation of new
and established antiretroviral drug interventions,
and (iv) the evaluation of novel induction and
killing approaches (106). Other humanized mouse
models have been successfully used to evaluate
broadly neutralizing antibodies and combina-
tion induction therapy, with encouraging results
(99, 107, 108). In addition, because humanized
mice represent a complex system featuring
virtually all cell types that are important for
adaptive immune responses, they can be useful
for the in vivo evaluation of novel approaches to
curing HIV that are based on biological mol-
ecules as well as gene and cell therapies.

Pathogenic models of SIV infection in the
rhesus macaque have also been used in HIV
cure research, following the formulation of ART
similar in composition, safety, and efficacy
to those that have been used in humans. ART
regimens now consistently suppress SIV viremia
to levels below detection (less than three copies
per milliliter of plasma) of the most sensitive
assays, thus reaching viral suppression compa-
rable with that in HIV-infected humans (109–111).
The availability of such sensitive viral detection
assays in both animal models may now allow the
field to address critical questions in the context of
ongoing ART in vivo.

Thus, human testing of latency reversal and
clearance strategies is needed. In selected set-
tings, experimental agents that have already
advanced to human testing in venues such as
oncology may be more rapidly brought forward
for proof-of-concept studies in man. But initial
evaluation of novel agents or combinations will
still likely require testing in animal models.
Where exhaustive analysis of tissue is needed,
animal models will continue to be integral to
research advances, although when possible, im-
mune tissues in human clinical trials should be
examined. For example, specialized structures
in lymph nodes called lymphoid follicles are en-
riched for viral infection, and CTL responses have
recently been shown to be restricted at these sites
(112). The ability of diverse eradication
strategies to deliver effectors to such potential
sanctuaries can be carefully tested only in such
in vivo models.

Conclusion: The synergies of cure
and prevention

Research toward HIV eradication began with
the success of ART, followed closely by the
description of latent, persistent infection. The
daunting problem of proviral latency and the
failure of initial eradication efforts (113) led to
a long hiatus in such efforts, but these were
renewed after the report of an HIV cure in the
Berlin patient (3) and the initial description of
a LRA (22). The next major advance will likely
be the demonstration, outside of the context
of bone marrow transplantation, of substantial
depletion of persistent infection when effective
LRAs are appropriately paired with a viral
clearance strategy that delivers active effector
cells to the sites of induced viral expression.
Years of longitudinal measurements have sug-
gested a benchmark for such trials: a decrease by
a factor of at least 6 of the frequency of replication-
competent HIV within the resting CD4+ T cell
reservoir after an intervention, a decline that is
rarely seen on ART alone. Such a depletion of
latent infection shown by means of QVOA would
be expected to correlate with a depletion of the
total replication-competent latent reservoir, a
meaningful step toward the goal of HIV eradic-
ation (38). Already, the decades of investment in
the development of a prophylactic HIV vaccine
and other preventive strategies have paid un-
expected dividends; this research pipeline pro-
vides key knowledge and research tools needed
to implement effective HIV clearance strategies.
However, it is very likely that additional advan-
tage will be gained through the development of
immunological strategies that either clear the
remission of viremia in the absence of ART or,
eventually, eradication of HIV infection. This
challenge is poignantly illustrated by the case
of the “Mississippi child,” in whom ART was
interrupted after treatment for the first 18
months of life, and a remission of viremia lasted
27 months before a robust viral rebound mimick-
ing primary infection (6). In this child, the viral
reservoir was too small to measure, and aviremia
in the absence of an HIV-specific immune
response presumably was maintained by the
intrinsic quiescence of latently infected cells.
This scenario also suggests a third interven-
tion that should be added after therapeutic
disruption of HIV latency and clearance of cellular reservoirs of persistent infection; protection against viral rebound and new HIV infection. As the field of HIV vaccine development moves forward, prophylactic vaccines should be deployed as the last step in an HIV latency reversal and clearance strategy, both to prevent viral rebound that might emanate from rare latently infected cells that have survived the initial rounds of latency reversal and clearance, and to protect against new HIV infection in this at-risk patient population. The prevention of re-infection is an important public health measure, given the substantial health care investment likely to be needed to achieve durable remission or cure of HIV infection.

The past 5 years have seen a substantial new investment in HIV cure research from governments, foundations, and industry. Advances and new insights into the nature of the problem have marked the founding of this new field of endeavor. Key insights into the diverse and complex biology of persistent HIV infection have been made. A diverse portfolio of LRAs is under study, and a pipeline for the development, testing, and validation of new agents now exists. A variety of approaches to imbue an effective anti-HIV response to mediate viral clearance are under study, and some are entering clinical testing. Clearly much work and many challenges lie ahead, but if novel scientific insights can be brought to bear in clinically effective ways, the era marked by the benefits of ART may be brought to bear in clinically effective ways, the era marked by the benefits of ART may be.
m. j. buzon et al., specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 570–573 (2014). doi:10.1126/science.1256304;
J. A. Suri et al., Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. Cell Host Microbe. 21, 258–263 (2017). doi:10.1016/j.chom.2017.05.009; pmid: 28593535;
F. Garcia, A. Leon, J. M. Gatell, M. Plana, T. Gallart, Antiviral Therapy, Miami, FL, 8–11 September 2013. doi:10.1007/978-3-319-04271-5_19; pmid: 24052700;
S. D. Sloan et al., Targeting HIV reservoir in infected CD4 T cells by dual-affinity re-targeting molecules (DARTs) that bind HIV envelope and recruit cytotoxic T cells. PLoS Pathog. 9, e1003523 (2013). doi:10.1371/journal.ppat.1003523; pmid: 26539583;


ACKNOWLEDGMENTS

The authors thank N. Goonetilleke for valuable input. D.M.M. and B.F.H. have filed patent application PCT/US2015/053027 related to dual-affinity retargeting antibodies. Work in the authors’ laboratories was supported by the National Institutes of Health grants U19-AI096113 to D.M.M., UM1-AI10064 for the Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery to B.F.H., RO1-AI111899 and R01-MH108179 to J.V.G. and P30-A150410 to the University of North Carolina Center for AIDS Research. We thank all the HIV+ participants in our studies for their critical contributions to this research.
Latency reversal and viral clearance to cure HIV-1
David M. Margolis, J. Victor Garcia, Daria J. Hazuda and Barton F. Haynes

Science 353 (6297), aaf6517.
DOI: 10.1126/science.aaf6517

**Next steps toward curing HIV-1**

Since the discovery of HIV-1 more than 30 years ago, prevention and treatment strategies have dominated the research agenda. More recently, however, scientists are also focusing their efforts toward finding a cure. Margolis et al. review an approach that involves HIV-1 latency reversal and viral clearance. The idea is to reactivate any dormant virus and coax it to produce viral proteins that the immune system can recognize. By combining a latency reversal strategy with immunotherapies, the body might be able to rid itself of all infected cells.

*Science*, this issue p. 362